Honasa Q1 FY27: consol PAT doubles YoY to ₹90 Cr as OPM jumps ~690bps to 14.6%
PAT +118.9% YoY · revenue +27% · margins expanding
₹755.95 Cr
+27% YoY
₹90.45 Cr
+118.9% YoY
11.62%
+4.9pp YoY
₹2.77
Consolidated revenue from operations rose 27.0% YoY to ₹755.9 Cr (₹595.3 Cr in Q1 FY26) and 15.0% QoQ from ₹657.1 Cr; PAT jumped 118.9% YoY to ₹90.4 Cr (₹41.3 Cr) and 30.3% QoQ (₹69.4 Cr), with basic EPS at ₹2.77 versus ₹1.27 a year ago and ₹2.13 last quarter. Neither the current nor the year-ago quarter carries an exceptional item, so the reported growth rate is also the clean underlying rate — profit growth comfortably outran revenue growth, the signal that makes this a margin-led beat rather than just a top-line story.
Q1 FY-2027 vs prior quarters
Operating margin (EBITDA/revenue-from-ops) expanded roughly 690 bps YoY to 14.58% (7.70% in Q1 FY26) and about 283 bps sequentially from 11.75%, while net margin widened to 11.62% of total income from 6.67% a year ago. The expansion tracks management's stated channel/brand-spend leverage playbook and clears the "double-digit operating margin" floor the company flagged ahead of results. Standalone (parent-only) PAT was ₹84.3 Cr on revenue of ₹696.3 Cr, up a slower 19.3% YoY — the gap versus consolidated's 27.0% points to subsidiaries and the JV (BBlunt salons, overseas units, BTM Ventures) growing faster than the parent book; readers comparing the two should note this divergence rather than treat either figure as the anomaly.
The stock went into the print at ₹479, up 1.8% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters.
Management is confident in delivering a high-teens CAGR over the next 5 years, with a target of 500 basis points EBITDA expansion during the same period. They anticipate continued strong growth from young brands and focus categories, with Mamaearth projected to achieve a double-digit CAGR over the next 5 years and expa
— This quarter: met
Against its own July 9, 2026 quarterly update, management had guided ~30% YoY underlying growth but explicitly flagged that reported-basis growth would land in the mid-20s because Flipkart changed its marketplace reporting convention, netting fulfilment/logistics costs before paying Honasa for goods sold. The actual 27.0% reported print sits inside that guided band, so this reads as a "met" on revenue, not a beat or a miss — margin came in ahead of the stated double-digit floor. No independent analyst PAT consensus for the quarter turned up in search, so the print cannot be graded against Street numbers; no separate management press-release commentary was available for this filing. On the legal front, the Dubai Cassation Court on July 29, 2026 upheld a ~₹4.3 Cr (AED1.75 mn) compensation order against Honasa in the RSM distributorship dispute, while a separately-seated Delhi arbitration tribunal (award dated May 14, amended June 26, 2026) went the other way, awarding Honasa ~₹25.5 Cr (AED9.92 mn) plus further damages from RSM — neither figure is booked in this quarter's P&L, since exceptional items are nil in both the current and comparative columns.
W1
Whether OPM (14.58% this quarter, +690bps YoY) sustains as revenue growth normalizes toward management's ~30% underlying target versus this quarter's mid-20s reported print.
W2
Cash recovery status of the ~₹25.5 Cr (AED9.92mn) Delhi arbitration award against RSM — not yet reflected in the balance sheet or P&L.
W3
Progress on the Fluence Pharma acquisition (58% stake, board-approved Jun 23, 2026) toward closing and first-quarter consolidation.
Clean typed statement, figures in Rs. Million converted to Cr (÷10); arithmetic checks exact for both standalone and consolidated. Consolidated PBT includes a ₹0.057 Cr share of JV profit; NCI is immaterial (PAT attributable to owners ₹90.249 Cr of ₹90.448 Cr total). No exceptional items in current or year-ago quarter columns (the ₹4.797 Cr labour-code exceptional charge sits only in the FY26 full-year column), so no adjusted-growth calc is needed.
Growth on Guidance, Margins the Test
Honasa enters Q1 FY27 results day projecting 30% revenue growth and double-digit operating margins—Street is cautiously bullish, but execution on Fluence integration and offline scaling will determine if the stock justifies its 92% run from 52-week lows.
The Setup: Growth Engine on Test
Honasa reports Q1 FY27 results on August 13 riding a surge that has lifted the stock 92% from its 52-week low. The narrative is straightforward: 30% revenue growth (unadjusted; mid-20s on reported basis after Flipkart policy shifts), sustained double-digit operating margins, and a strategic pivot into wellness via the Fluence Pharma acquisition (58% stake for ₹135 crore). But Street consensus is cautiously bullish—the stock has run, valuation concerns linger, and the real test is whether management can deliver margin expansion while scaling faster than peers. Miss on guidance or stumble on Fluence integration, and the re-rating narrative reverses.
~30%
Management guided for strong Q1 growth; mid-20s on reported basis (Flipkart policy adjustment)
~double-digit
Honasa committed to maintaining double-digit operating margins; offline expansion is key lever
~24–25%
Analyst consensus for FY27; dependent on Q1 execution setting the tone
high-teens growth
Core growth engine; younger portfolio brands (Derma Co, Aqualogica, etc.) tracking early 40s
On Track? The Prior Trajectory
Honasa closed FY26 with ₹200 crore PAT (double-digit growth trajectory), Q4 FY26 revenue at ₹682 Cr (28% YoY growth), and EBITDA at ₹77 Cr—a foundation of momentum. The company has signaled confidence in FY27 earnings growth of 24–25% and articulated a long-term goal of doubling EBITDA margins over FY24–30. Q1 FY27, if it delivers 30% revenue growth at sustained margins, would set a healthy baseline for that ambition. The wildcard: Fluence integration and whether the nutraceuticals addition dilutes or accels overall margin profile (initial market reaction was mixed: stock fell 4% on deal announcement, though analysts support the strategic diversification).
What the Street Says
Since Last Quarter: The Event Scan
1 · Fluence Pharma Acquisition (Jun 23, 2026)
Honasa acquired 58% stake in science-backed nutraceuticals company for ~₹135 Cr. Strategic entry into India's ₹16,000+ Cr wellness market. Initial market reception mixed (stock fell 4% on deal news), but analysts support the portfolio diversification. Integration timeline and margin accretion are key watches; Street expects positive synergies with derma portfolio (The Derma Co, Aqualogica).
2 · CMO Appointment (Aug 6, 2026)
Nilesh Kotalwar elevated from SVP–Online Revenue to Chief Marketing Officer, effective Aug 6. Signals focus on brand-building and positioning ahead of reported results. Limited material impact on Q1 earnings, but demonstrates continued leadership investment.
3 · FY26 Dividend & Subsidiary Move (May–Jul 2026)
Board recommended maiden final dividend of ₹3 per share (30% payout) for FY26. Honasa Health Private Limited incorporated as wholly owned subsidiary on Jul 7, 2026—preparation for potential health/wellness vertical expansion (synergistic with Fluence). Insurance Trading window closed from Jul 1 until 48 hrs after Q1 result submission.
4 · Arbitration Win Rectified (Jun 26, 2026)
Honasa won rectification order in arbitration vs. RSMM General Trading LLC; award increased to AED 9.9M (~₹21 Cr). Initial award was ₹18.88 Cr. Non-cash item, but demonstrates successful dispute resolution and potential future collectible. Routine governance and risk management.
What to Watch on Result Day
1 · Revenue Growth Confirmation
Is Honasa tracking the 30% YoY growth (unadjusted) it guided for? Peel the onion: Mamaearth (high-teens growth), younger brands (Derma Co, Aqualogica, BBlunt, Dr. Sheth's—early 40s), and offline expansion metrics (outlet count, distribution %). Any shortfall here resets growth narrative and invites re-rating pressure.
2 · Operating Margin Trajectory
Did Honasa sustain double-digit operating margins despite higher inflation/logistics costs? This is where execution on offline scaling (target 400k+ retail outlets) and operational leverage matter most. If margins compress, Street will question the long-term 2x EBITDA-margin ambition. If margins are stable or expand, bulls have the narrative.
3 · Fluence Pharma Integration Clarity
Any early commentary on nutraceuticals ramp, distribution strategy, or expected contribution to FY27 PAT? Management will likely provide a timeline for profitability and margin contribution. Street is watching for execution risk; a credible plan de-risks the initial negative reaction.
Honasa enters Q1 FY27 results with a strong growth narrative (30% revenue, 24–25% PAT) and a strategic acquisition that diversifies beyond D2C beauty into wellness. The stock has priced in this optimism, up 92% from the 52-week low. Street consensus is bullish, but valuation discipline is intact—the print must deliver on guidance. Watch revenue confirmation, margin sustainability, and early Fluence signals. A beat could push the Jefferies bull case (₹610); a miss invites sharp compression. This is an execution quarter.